Heather McCreery

Statistics

Publications

Citations

319

H-Index

Active since

2001

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

Heather McCreery is an author at The University of Texas at San Antonio Health Science Center specializing in pharmacology, pharmacokinetics, and pharmacokinetics of anticancer drugs.

Publications per year

2001–2006

Publications

A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

Carolyn D. Britten, Eric K. Rowinsky, Steven L. Soignet et al. · PubMed · 2001 · 88 citations

Pharmacy, Pharmacokinetics, Pharmacology +9

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

Emiliano Calvo, Anthony W. Tolcher, Lisa A. Hammond et al. · Clinical Cancer Research · 2004 · 81 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

Alain C. Mita, Lisa A. Hammond, Peter L. Bonate et al. · Clinical Cancer Research · 2006 · 67 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

Desirée Hao, Lisa A. Hammond, Sabine Eckhardt et al. · PubMed · 2003 · 50 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

Amita Patnaik, S. Gail Eckhardt, Elżbieta Izbicka et al. · PubMed · 2003 · 33 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

1–5 of 5